R&R CBD Brand Report Card

BR-007 · Documentation Review

Brand: R&R CBD. Report-card status: Concern. R&R provides strong public lot-specific lab access, broad testing disclosures, a 60-day guarantee, flexible subscription cancellation, and relatively careful THC reporting. The main concerns are conflicting live pricing/subscription displays and broad health, effect-timing, and potency-selection claims.

Brand Report Card

Check	Result	Current evidence
COA access	Pass	R&R maintains a public lab-testing directory organized by product form, strength, spectrum type, and lot number.
Batch matching	Pass	PP-007 matched the 30mg full-spectrum Multifunctional CBD Gummies to lot 2408, which remains listed in the current lab directory.
Test-panel coverage	Unknown	R&R says every batch is tested for potency, terpenes, microbes, heavy metals, residual solvents, and pesticides. PP-007 included broad contaminant panels, but CBDCafe has not sampled enough current products to score every brand category as Pass.
Label clarity	Concern	Multiple live product URLs can show different one-time and subscription pricing for the same 30mg gummy line, and current pages mix measurable product facts with strong health, onset, duration, and potency-selection guidance.
THC wording	Pass with context	Full-spectrum pages disclose trace THC below 0.3%. Broad-spectrum THC-free pages define the claim as non-detectable THC by third-party HPLC and still caution people subject to testing.
Refund terms	Pass	Current product and collection pages consistently describe a 60-day money-back guarantee.
Subscription cancellation	Pass	The current Subscribe & Save page says customers can swap products, skip shipments, or cancel at any time through account controls.
Customer service test	Not Tested	CBDCafe did not contact customer service for BR-007.
FDA warning-letter check	Pass with limitation	CBDCafe did not identify R&R CBD or R&R Medicinals in FDA’s current warning-letter search. Absence from an FDA search is not approval or certification.
Evidence freshness	Pass	Lab access, PP-007 lot mapping, refund language, subscription controls, THC wording, and current seller claims were rechecked September 5, 2026.

Public Lot-Specific Lab Directory

R&R’s current lab-testing page organizes certificates by category, potency, and spectrum type. The 30mg full-spectrum gummy section still lists lot 2408, the lot reviewed in PP-007, alongside a newer lot.

The brand says every batch is tested with third-party laboratories for potency, terpene profile, microbes, heavy metals, residual solvents, and pesticides.

View R&R lab testing · Read PP-007

THC Wording Gives More Context Than Many Sellers

R&R’s full-spectrum pages disclose trace THC below 0.3%. Its broad-spectrum THC-free pages include a footnote defining THC-free as non-detectable levels of THC according to HPLC analysis by third-party labs.

The same pages still advise people who are subject to testing not to use the product. CBDCafe treats that as more careful wording than an absolute-zero or pass-your-drug-test promise.

See THC-Free CBD and Non-Detect for why reporting limits still matter.

Pricing and Subscription Displays Need More Consistency

R&R’s formal Subscribe & Save page says subscribers save 20% on each order and can swap, skip, or cancel at any time. Some live individual product pages display much larger subscription savings, such as approximately 40%, while other live product or bundle pages display 20%.

Because the cancellation controls are clear, Subscription Cancellation remains Pass. The inconsistent displayed savings and duplicate product-page pricing contribute to the Label Clarity Concern instead.

R&R Subscribe & Save

Health and Use Claims Are Broad

Current R&R pages market products for pain, stress, sleep, inflammation, focus, mental clarity, and other outcomes. Some pages also tell shoppers which potency to choose based on symptom severity, how often to use products, and how quickly results may occur.

CBDCafe records that those statements are part of the current seller documentation but does not score them as verified treatment, symptom-relief, onset, duration, or personal dosing evidence.

Refund Terms Are Consistent

Current R&R product and collection pages repeatedly describe a 60-day money-back guarantee. Some pages encourage consistent use before requesting a refund, but the published window itself is consistent across the reviewed pages.

Review Scope

Report Card ID: BR-007
Review level: Documentation Review
Commercial relationship: No commercial tie recorded
Customer service test: Not Tested
Last checked: September 5, 2026
Current status: Concern

Important: This Brand Report Card evaluates dated public documentation and policies. It is not an endorsement, medical recommendation, legal opinion, laboratory certification, drug-test promise, or guarantee that every R&R product or future batch will match the sampled evidence.